Aviva PLC Trims Position in Eli Lilly and Company (NYSE:LLY)

Aviva PLC cut its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 494,111 shares of the company's stock after selling 18,921 shares during the quarter. Eli Lilly and Company accounts for approximately 1.0% of Aviva PLC's holdings, making the stock its 13th largest position. Aviva PLC owned approximately 0.05% of Eli Lilly and Company worth $381,454,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in LLY. Highline Wealth Partners LLC increased its position in Eli Lilly and Company by 80.0% during the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after acquiring an additional 20 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its stake in shares of Eli Lilly and Company by 117.1% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 46,132 shares of the company's stock worth $41,000 after purchasing an additional 24,879 shares during the period. FPC Investment Advisory Inc. boosted its holdings in shares of Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after buying an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $48,000. Finally, Compass Financial Services Inc purchased a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $50,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Down 1.2 %

Shares of NYSE:LLY traded down $8.85 during trading hours on Tuesday, hitting $714.88. The company's stock had a trading volume of 2,938,936 shares, compared to its average volume of 3,671,757. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The firm's fifty day moving average price is $846.64 and its 200 day moving average price is $830.05. The company has a market capitalization of $677.83 billion, a price-to-earnings ratio of 60.99, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its board has initiated a share repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Bank of America reiterated a "buy" rating and set a $997.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Citigroup cut their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Truist Financial raised their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $1,018.89.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.